A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
4期
已完成
NCT06229145
| 适应症 | Gout |
|---|
| 分期 | 4期 |
|---|
| 申办方 | Amgen |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 262 人 |
|---|
| 干预（药物） | Pegloticase, Methotrexate |
|---|
| 开始日期 | 2024年3月18日 |
|---|
| 完成日期 | 2025年7月30日 |
|---|
| 结果公布日 | 2026年7月1日 |
|---|
摘要
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to \< 6 mg/dL for at least 80% of the time.
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Month 6 (Weeks 20, 21, 22, 23, and 24) · percentage of participants
| Pegloticase 8mg Q2W + MTX | 70.8 percentage of participants |
|---|
| Pegloticase 16mg Q4W + MTX | 56.5 percentage of participants |
|---|
| p-value | 0.10 |
|---|
| Response rate difference | 12.7 (95% CI 1.2–24.1) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。